Earnings Call Summary | Stepan(SCL.US) Q2 2024 Earnings Conference
Earnings Call Summary | Stepan(SCL.US) Q2 2024 Earnings Conference
The following is a summary of the Stepan Company (SCL) Q2 2024 Earnings Call Transcript:
以下是史提賓公司（SCL）2024年第二季度業績會簡報：
Financial Performance:
金融業績：
Stepan Company reported a second quarter adjusted EBITDA of $47.7 million, up 4% year-over-year.
Net sales in Q2 2024 decreased by 4% year-over-year, mainly due to lower selling prices which were partially offset by a 4% increase in global sales volume.
Free cash flow for the first half of the year was reported at $11 million, with the company remaining confident in achieving positive free cash flow by the end of 2024.
史提賓公司報告2024年第二季度調整後EBITDA爲4770萬美元，同比增長4%。
2024年第二季度淨銷售額同比下降4％，主要由於低銷售價格，部分抵消了全球銷售量增長4％。
今年上半年的自由現金流爲1100萬美元，公司仍有信心在2024年底實現正面自由現金流。
Business Progress:
業務進展：
The company is on track to meet its $50 million cost reduction goal for 2024.
Significant volume growth was noted in Surfactants, particularly in the Laundry and Cleaning, Construction, Industrial Solutions, and Oilfield end markets, as well as in Latin American markets.
Stepan's Polymers business saw an increase in Rigid and Specialty Polyols volumes, albeit partially offset by lower Phthalic Anhydride volumes due to production issues.
該公司正朝着實現2024年5,000萬美元的成本削減目標的方向發展。
表面活性劑市場的成交量顯著增長，特別是在洗衣和清潔，建築，工業解決方案和油田終端市場以及拉美市場。
史提賓的聚合物業務看到硬質和專用聚醇體積增長，儘管由於生產問題而部分抵消了鄰苯二甲酸酐的體積下降。
Opportunities:
機會：
The company continues to experience strong volume growth in several core markets, which supports the ongoing investment in business operations and return of cash to shareholders.
該公司在幾個核心市場繼續經歷強勁的成交量增長，支持業務運營的持續投資和向股東返還現金。
Risks:
風險：
Operational issues at the Millsdale site led to higher costs.
A fraud event in one of the company's Asian subsidiaries resulted in a $3.5 million pre-tax charge for the quarter, with an expected similar charge in Q3.
Millsdale工廠的運營問題導致成本上升。
公司在一個亞洲子公司遭遇欺詐事件，導致本季度稅前費用爲350萬美元，並預計在第三季度產生類似費用。
More details: Stepan IR
更多細節：史提賓IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。